/ciol/media/agency_attachments/c0E28gS06GM3VmrXNw5G.png)
Follow Us/ciol/media/post_banners/wp-content/uploads/2022/11/Agatsa.jpg)
Agatsa is a provider of a rapid assessment of cardiac health for both non-doctors and health care practitioners. Its mission is to revolutionize healthcare through technology. The startup was founded in 2015 by Rahul Rastogi and Neha Rastogi.
The main aim is to make cardiac monitoring more affordable and accessible for everyone. Its products - SanketLife (World's first touch-based 12-lead ECG machine) and Multivital 2.0 - enable users to quickly capture their heart data, create a report on their smartphones, and share it with doctors. Agatsa has raised INR 125 in its Pre-Series A round and has won many prestigious awards since its inception.
Speaking to CIOL, Rahul Rastogi, CEO and Founder, Agatsa has shared his views on the growing need of cardiovascular monitoring device in India. He talked about his startup journey and also, and he speaks about the growth plans he has for Agatsa.
Tell us about Agatsa and your offerings. Tell us about the team.
Agatsa is a leading provider of connected and affordable Medtech devices, powered by AI. Agatsa's Technology is used by both physicians and common people. Headquartered in Noida, the health tech company aims to enable easy monitoring of people's cardiac health at home using AI technology. The startup pioneered the development of the world's smallest 12-lead ECG device, SanketLife.
Founded in 2014 by a husband-and-wife team, the company's mission is to transform healthcare by paving the way for remote and preventive healthcare. The company has developed several other products such as SanketLife Pro Plus and Multivital 2.0 to expand the horizon from heart health to other patient parameters. Agatsa's vision is to make healthcare accessible and affordable to everyone living in the community. The company has a talented team of around 60-70 people.
What are the drivers/market trends that are shaping the Medical landscape in 2022?
The Covid-19 pandemic has a significant role to play in shaping the medical landscape. Earlier people were not very much concerned about their health and needed a push that has been provided by the pandemic. As a result, individuals have become proactive in taking care of themselves rather than waiting for them to fall ill and initiate treatment. Individuals are becoming health-conscious day by day and their urge to have a medical device in hand increases the demand for it.
Tell us about the recent development in your company. Any changes for Agatsa?
The Made in India company is on a mission to provide healthcare products at an affordable price with multiple features. The startup is continuously working on including additional features in the existing product line to make India self-reliant and thus contributing towards increasing countries' GDP. We will continue to build products to minimize the healthcare gap existing within the ecosystem.
How has your revenue grown with brand evolving during pandemic?
Our revenue numbers had a multifold increases in the initial months of Covid-19. We will be opening a second production unit in Andhra Pradesh MedTech Zone (AMTZ)to meet the growing demand forour device.
What has 2021 changed for you? How are things now?
While many businesses have faced obstacles during COVID-19, the medical and health-tech sector has gained momentum. Not only physicians but even individuals have also realized the importance of self or remote monitoring. Covid-19 has resulted in a sudden increase in the demand of our devices, which is a clear indicator of the adoption of digital healthcare and I believe platforms like ours can bring true digitalization in the ecosystem.
What are your growth priorities for 2022?
The consumers are now well-informed and eager to stay healthy. Thus, taking in consideration the consumer mindset, we are including wearables and patches into our product line helping individuals to monitor their health 24/7. Since our product is Made in India and to meet the growing demand, we will be hiring more manpower to fulfill it.
Funding
Agatsa is in talks of raising Series B Funding. In the last round of series A Funding, the company raised INR 125 million.